These authors contributed equally to this work Purpose: Karyopherin alpha 2 (KPNA2) has been reported as an oncogenic protein in numerous human cancers and is currently considered a potential therapeutic target. However, the transcriptional regulation and physiological conditions underlying KPNA2 expression remain unclear. The aim of the present study was to investigate the role and regulation of interferon regulatory factor-1 (IRF1) in modulating KPNA2 expression in lung adenocarcinoma (ADC). Materials and methods: Bioinformatics tools and chromatin immunoprecipitation were used to analyze the transcription factor (TF) binding sites in the KPNA2 promoter region. We searched for a potential role of IRF1 in non-small-cell lung cancer (NSCLC) using Oncomine and Kaplan-Meier Plotter datasets. qRT-PCR was applied to examine the role of IRF1 and signaling involved in regulating KPNA2 transcription. Western blotting was used to determine the effects of extracellular stimulation and intracellular signaling on the modulation of KPNA2-related TF expression. Results: IRF1 was identified as a novel TF that suppresses KPNA2 gene expression. We observed that IRF1 expression was lower in cancerous tissues than in normal lung tissues and that its low expression was correlated with poor prognosis in NSCLC. Notably, both ataxia telangiectasia mutated (ATM) and mechanistic target of rapamycin (mTOR) inhibitors reduced KPNA2 expression, which was accompanied by increased expression of IRF1 but decreased expression of E2F1, a TF that promotes KPNA2 expression in lung ADC cells. IRF1 knockdown restored the reduced levels of KPNA2 in ATM inhibitor-treated cells. We further demonstrated that epidermal growth factor (EGF)-activated mTOR and hypoxiainduced ATM suppressed IRF1 expression but promoted E2F1 expression, which in turn upregulated KPNA2 expression in lung ADC cells. Conclusion: IRF1 acts as a potential tumor suppressor in NSCLC. EGF and hypoxia promote KPNA2 expression by simultaneously suppressing IRF1 expression and enhancing E2F1 expression in lung ADC cells. Our study provides new insights into targeted therapy for lung cancer.
Introduction
Karyopherin alpha 2 (KPNA2, also known as importin α1) is a member of the importin α family and transports cargo containing a canonical nuclear localization signal by forming an importin α/β/cargo heterotrimer. 1, 2 Due to its function in nucleocytoplasmic transport, KPNA2 is involved in many cellular processes, including differentiation, development, viral infection, the immune response, transcriptional regulation and cellular maintenance. 3 Recently, several studies have linked KPNA2 to cancer. During the past decade, KPNA2 overexpression has been reported in at least 18 human cancer types, such as lung, breast, colon and bladder cancer. A high level of KPNA2 is positively associated with cancer invasiveness and poor prognosis in patients, thus establishing KPNA2 as a potentially relevant therapeutic target. 3, 4 We previously identified KPNA2 as a potential biomarker for lung ADC, and we observed that KPNA2 overexpression promotes the proliferation and migration of lung ADC cells. 5 We applied proteomic approaches to search for differentially expressed protein profiles and invasiveness-associated KPNA2−vimentin−pErk complexes in lung ADC cells with siRNA-mediated knockdown of KPNA2. 6, 7 Notably, KPNA2 transports the oncogenes c-Myc and E2F1 and the tumor suppressor genes p53, NBS1 and BRCA1 into the nucleus, suggesting that spatiotemporal regulation of KPNA2 is crucial for its role in tumorigenesis. 6, [8] [9] [10] Our recent study showed that the mTOR pathway is involved in the regulation of KPNA2 protein turnover and correlates with Dp1/E2F1mediated KPNA2 transcription. 11 However, the upstream signaling pathway and the transcription factor (TF) responsible for regulating KPNA2 expression are still unclear.
Interferon regulatory factor-1 (IRF1), a TF belonging to the IRF family, regulates IFN-β and IFN-related gene expression. 12 Accumulating evidence supports the notion that IRF1 has multiple functions in gene expression regulation during inflammation, immune responses, cell proliferation, cell cycle progression, T cell differentiation, and DNA damage. [13] [14] [15] Notably, IRF1 is also involved in cancer biology, but its role in cancer progression is controversial. Gene alteration and/or low expression of IRF1 are correlated with poorer clinical outcomes, high cancer susceptibility and low immunotherapy response, suggesting that IRF1 is a tumor suppressor in multiple cancer types, such as leukemia, breast cancer, cervical cancer and colorectal cancer. [16] [17] [18] [19] However, the oncogenic ability of IRF1 in hepatocellular carcinoma and esophageal cancer was recently reported. [20] [21] [22] These studies suggest that the role of IRF1 in cancer is cancer-type specific.
In the present study, we identified IRF1 as a novel transcriptional suppressor of KPNA2 in lung ADC cells. We further investigated the signaling pathways and physiological conditions involved in IRF1-mediated KPNA2 expression in lung ADC cells.
Materials and Methods

Reagents and Antibodies
Epidermal growth factor (EGF), rapamycin, ATM inhibitor and β-actin antibody (MAB1501) were purchased from Millipore (Bedford, MA, USA). KPNA2 (sc-55538), E2F1 (sc-251), IRF1 (sc-497) and ATM (sc-23921) antibodies were obtained from Santa Cruz (California, USA). Phospho-ATM (Ser1981), p70S6K, phospho-p70S6K (Thr389), mTOR, phospho-mTOR (Ser2448), IRF1 and Slug antibodies were obtained from Cell Signaling (Beverly, MA, USA). Hypoxia inducible factor 1α (HIF-1α) and lactate dehydrogenase A (LDHA) antibodies were purchased from GeneTex (Irvine, California, USA) and Abcam (Cambridge, Massachusetts, USA), respectively.
Cell Culture
A549 ADC, NCI-H520 squamous cell carcinoma (SCC) and NCI-H460 large-cell carcinoma (LCC) cell lines were purchased from Food Industry Research and Development Institute (Hsinchu, Taiwan). CL1-5 ADC cell line was derived from one man with poorly differentiated lung ADC 23 and kindly provided by Professor P.C. Yang (Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan). A549 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Invitrogen, Carlsbad, CA, USA), and CL1-5, NCI-H520 and NCI-H460 cells were cultured in RPMI 1640 (Gibco). All media were supplemented with 10% fetal bovine serum (Gibco), 100 units/mL penicillinstreptomycin (Gibco), and 2 mM L-glutamine (Gibco). The cells were incubated at 37°C in a humidified atmosphere comprising 95% air/5% CO 2 .
Small Interfering RNA Transfection
Cells were transfected for 24 h with 10 nM negative control (NC) small interfering RNA (siRNA), siRNA against IRF1 (GGGCUCAUCUGGAUUAAUA, GCUCAGCUGUGCG AGUGUA, Dharmacon, Lafayette, USA) or siRNA against KPNA2 (GAAAUGAGGCGUCGCAGAA, GAAGCUA CGUGGACAAUGU, AAUCUUACCUGGACACUUU, GU AAAUUGGUCUGUUGAUG, Dharmacon, Lafayette, USA) with Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA, USA). 
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed as described previously. 11 Briefly, the crosslinked, sonicated chromatin obtained from lung cancer cells was precleared with Dynabeads Protein G (Invitrogen) before the chromatin samples were incubated with E2F1 or IRF1 antibodies on a rotator at 4°C overnight. Dynabeads Protein G were added for an additional 15 min. Mouse IgG antibody (Santa Cruz Biotechnology) was used as the immunoprecipitation control. After extensive washes, the immunecomplexes were treated with proteinase K and decrosslinked at 65°C for 6 h. Bound DNA was extracted with a PCR purification kit (Qiagen, Chatsworth, CA, USA) and subjected to PCR analysis using KPNA2 primers designed to span the E2F1 and IRF1 binding sites. The sequences of primers are listed as follows: IRF1 #1, sense 5ʹ-AGATAGCAAATT GTAAGGAGGG-3ʹ and antisense 5ʹ-GTGCCAGGGCAA TAAATTC-3ʹ; IRF1 #2, sense 5ʹ-GAGCCTCCTGAGGAT CT-3ʹ and antisense 5ʹ-CCAAATAGTATTTCAACGTGT TATCA-3ʹ; IRF1 #3, sense 5ʹ-CTCCAGGAAGTCTCAGC -3ʹ and antisense 5ʹ-TATGAGACAAAGGGAGAAAGC TAA-3ʹ; and E2F1, sense 5ʹ-ATGGGCACACAGCTTAG-3ʹ and antisense 5ʹ-CTGAGTCTGTACCTGCGAA-3ʹ.
Cell Viability Assay
Cells (5×10 3 cells/well) were plated in 24-well plates and cultured for the indicated time intervals. After culture, cell viability was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide (MTT) colorimetric growth assay as described previously. 5
Western Blotting Assay
Protein extracts were resolved by SDS-PAGE and transferred to PVDF membranes using a Tris-glycine buffer system. The membranes were incubated with primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies and developed using a chemiluminescent HRP substrate (Merck Millipore, Darmstadt, Germany).
Hypoxia Treatment
Cells were seeded in 6-well plates, incubated under normoxic conditions overnight and then transferred to hypoxia chambers (SCI-tive; Baker Ruskinn, Sanford MA) containing 1% O 2 for the indicated times. Oxygen dissolved in the media was removed for 4 h before it was replaced under hypoxic conditions. Cells were collected and lysed for Western blotting.
Statistics
All quantitative data are shown as the mean ± standard deviation (SD). Significant differences in mRNA expression between the two groups were assessed by the Mann-Whitney test. Significant differences in protein expression in response to different inhibitor treatments were assessed by unpaired t-test analysis. For cell viability assay, two-way ANOVA was used. All data were processed using GraphPad Prism 5.01 software. A p value of less than 0.05 was considered statistically significant.
Results
IRF1 Is a Potentially Suppressive TF Regulating KPNA2 Expression in Lung Adenocarcinoma Cells
To the best of our knowledge, E2F1/Dp1 and E2F7 are the best-known TFs involved in KPNA2 gene expression. 11, 24, 25 To identify the TF responsible for KPNA2 transcription, we applied the available online software programs PROMO 26 and TFBIND 27 to analyze putative TF binding sites in the KPNA2 promoter region (NC_000017.11., range from 68,035,602 to 68,046,859). Accordingly, 64 and 138 TF candidates were predicted via PROMO and TFBIND, respectively, to bind to the KPNA2 promoter sequences. Among these candidates, 20 TFs overlapped between these two programs: AP-1, ATF, C/EBPalpha, CREB, c-Jun, Elk-1, GATA-1/2/3, GR, HNF-1A, IRF-1, IRF-2, NF-1, NF-Y, p53, Pax-5, SRY, XBP-1 and YY1. Specifically, eleven canonical IRF1-binding elements on the KPNA2 promoter region were predicted; the region −854~-4 was predicted as the IRF1 binding region by both PROMO and TFBIND ( Figure 1A) . We then performed a ChIP assay with an IRF1 antibody and primers that spanned three putative IRF1 binding sites located in −854~-4 of the KPNA2 promoter region. Figure 1B and C demonstrate the positive amplification of two pairs of IRF1 primers in the A549 and CL1-5 cell lines, confirming the associations between IRF1 binding sites in the KPNA2 promoter. The positive binding of E2F1 to the KPNA2 promoter was included as a positive control. Next, RT-qPCR analysis of cells with IRF1 knockdown revealed that the transcriptional activity of KPNA2 increased by 50% and 13% in IRF1-knockdown A549 and CL1-5 cells, respectively ( Figure 1D and E). These results support a potential role of IRF1 in negatively regulating KPNA2 transcription in lung ADC cells. Our previous study showed that KPNA2 knockdown significantly reduced the viability of CL1-5 cells. Therefore, we performed a cell viability assay to examine the potentially suppressive role of IRF1 in cell proliferation and observed that IRF1 knockdown enhanced cell viability, whereas KPNA2 knockdown significantly diminished the increased viability induced by IRF1 knockdown ( Figure  1F ). This result suggests that IRF1 may inhibit lung cancer cell proliferation through suppression of KPNA2 expression.
IRF1 Is Downregulated in Cancerous Tissues, and Its Low Expression Correlates with Poor Survival in Lung Cancer Patients
Both the diagnostic and prognostic values of IRF1 in lung cancer are unclear. We therefore determined the clinical significance of IRF1 in lung cancer using Oncomine (www.oncomine.org), a cancer microarray database with web-based data mining characteristics, and Kaplan-Meier Plotter (http://kmplot.com), a database that integrates mRNA expression and clinical data from five types of human cancers. NSCLC, which includes ADC, SCC, LCC, and some rare subtypes, is the most common type of lung cancer, comprising approximately 85% of all cases. 28, 29 ADC is the most common subtype of lung cancer worldwide and is the predominant histological type of NSCLC. SCC accounts for approximately 20-30% of all lung cancers, representing the second most common type of NSCLC. LCC accounts for approximately 3-10% of NSCLC. 29, 30 Based on the Oncomine 4.5 database, we found that the IRF1 mRNA expression level was significantly lower (1.5-fold decreased, p<0.05) in NSCLC tissues than in normal lung tissues in six ADC, four SCC, and one LCC microarray datasets. These lung datasets were initially published by Bhattacharjee, 31 Su, 32 Stearman, 33 Beer, 34 Selamat, 35 Hou, 36 Wachi 37 and Garber 38 (Figure 2A ). Furthermore, the Kaplan-Meier Plotter showed that lower IRF1 mRNA expression was correlated with poor overall survival (OS) in 673 ADC patients and first progression survival (FPS) in 443 ADC patients ( Figure 2B ). This low expression of IRF1 in cancer tissues was also significantly correlated with worse FPS in 141 SCC patients but was not associated with OS in 271 SCC patients ( Figure 2C ). We also confirmed the IRF1 gene expression and outcome association based on TCGA RNA-seq data, which contains 979 NSCLC cancer tissues (483 ADC and 486 SCC) and 109 normal lung samples. We found that IRF1 gene expression levels in these NSCLC cancer tissues were significantly lower than those detected in normal tissues. The Kaplan-Meier Plotter analysis also demonstrated that low IRF1 expression was associated with a worse prognosis, including shorter OS (log-rank p=0.025) and disease-free survival (log-rank p=0.092), in 482 ADC and SCC patients.
These results collectively support the suppressive role of IRF1 in lung cancer progression.
Both the mTOR and ATM Pathways are Involved in Regulating KPNA2 Transcription by Modulating E2F1 and IRF1 Expression in Lung Cancer Cells
Our quantitative proteomics analysis revealed that KPNA2 is involved in the DNA damage stimulation response, DNA metabolic processes, DNA repair, cell cycle and cell migration. 6 The serine/threonine kinase ATM is an important cell cycle checkpoint kinase and a sensor to DNA damage and oxidative stress. [39] [40] [41] Our previous study also indicated that the mTOR pathway contributes to E2F1/Dp1-mediated KPNA2 transcription in lung cancer cells. 11 In this study, we treated cells with the mTOR inhibitor rapamycin (Rap) and an ATM inhibitor (ATMi) to test whether the mTOR and ATM pathways play a role in regulating E2F1/Dp1-and/or IRF1-mediated KPNA2 transcription. Figure 3A shows that these two inhibitors significantly reduced KPNA2 mRNA levels in two lung ADC cell lines. However, NCI-H520 SCC and NCI-H460 LLC cells showed only minor changes in the modulation of KPNA2 gene expression in response to both mTOR and ATM inhibitors. Importantly, the protein level of IRF1 was dramatically increased, but E2F1 expression was decreased in two lung ADC cell lines after Rap and ATMi treatment (p<0.05, unpaired t-test) ( Figure 3B and C). Similar results were observed in NCI-H520 cells treated with mTOR inhibitor. Unexpectedly, Rap increased E2F1 expression in NCI-H460 cells ( Figure 3B and C) . IRF1 knockdown restored the reduced level of KPNA2 in ATMi-treated A549 cells, further supporting the suppressive role of IRF1 in regulating KPNA2 expression in ADC cells ( Figure 3D) . These results collectively suggest that the mTOR and ATM pathways modulate E2F1 and IRF1 expression in NSCLC cells. However, IRF1 and E2F1 may play a specific and potent role in the regulation of KPNA2 gene transcription in lung ADC cells. We therefore propose that mTOR and ATM activation contribute to KPNA2 overexpression by suppressing IRF1 expression and enhancing E2F1 expression in lung ADC cells ( Figure 4E) . 
EGF Stimulation and Hypoxia Contribute to the Transcriptional Regulation of KPNA2 by Suppressing IRF1 Expression and Promoting E2F1 Expression
EGF and hypoxia are common in microenvironments that contribute to lung cancer progression. We tested whether these two factors promote KPNA2 expression by modulating IRF1 and E2F1 expression. We observed that EGF treatment enhanced KPNA2 and E2F1 but suppressed IRF1 protein expression in A549 ADC cells ( Figure 4A) . In contrast, EGF treatment significantly increased IRF1 levels in NCI-H460 LCC cells ( Figure 4B ). Western blotting revealed that the mTOR but not the ATM pathway was upregulated upon EGF treatment. We also found that hypoxia induced KPNA2 and E2F1 expression but reduced IRF1 expression in A549 ADC cells but not in NCI-H460 LCC cells ( Figure 4C and D) . The reduction in phospho-p70S6K levels and elevation of HIF-1α, Slug and LDHA levels represent the molecular changes induced by hypoxic stress. [42] [43] [44] [45] Accordingly, we propose that both EGF-activated mTOR and hypoxia-induced ATM signaling promote KPNA2 transcription by enhancing E2F1 expression and suppressing IRF1 expression in lung ADC cells ( Figure 4E ).
Discussion
IRF1 is one of the best-known IRF genes involved in cancer biology. Both oncogenic and antioncogenic roles of IRF1 have been documented. 16, 18 Specifically, IRF1 activates several target genes associated with cell cycle regulation, growth suppression, apoptosis induction and immune responses, and these genes are responsible for the antitumor activity of IRF1. KPNA2 is a common oncogenic protein in numerous cancers, and KPNA2 overexpression is involved in the malignant transformation of cancer cells. 3, 4, 46 Herein, we identified IRF1 as a novel and negative regulator of KPNA2 transcription, which supports the theory that IRF1 plays an antioncogenic role by modulating the susceptibility of cells to transformation via oncogenes such as KPNA2. As a tumor suppressor, IRF-1 can be inactivated by a loss of heterozygosity at the DNA level, exon skipping at the mRNA level, and SUMOylation or oncoprotein interaction at the protein level. 18 We show that activation of both mTOR and ATM was involved in negatively regulating IRF1 expression. The knowledge regarding the regulation between ATM and IRF1 is limited. In human fibroblasts and malignant melanoma cells, IRF1 is upregulated and stabilized through an ATM-dependent pathway in response to irradiation or genotoxic stress. 18, 47 In addition, mTOR signaling has been reported to be suppressed by ATM-induced LBK1/AMPK/ TSC2 under oxidative stress independent of DNA damage. 48 These studies and ours suggest that the regulation of IRF1 is dependent on the cell type. The molecular mechanisms of mTOR-and/or ATM-mediated suppression of IRF1 in cancer cells require further exploration in the future.
Hypoxic stress triggers alterations of the microenvironment surrounding the tumor tissue via different adaptive mechanisms that promote cancer progression, including cell proliferation, glucose metabolism, inflammation, angiogenesis, and epithelial-mesenchymal transition. 49, 50 Specifically, HIF is the master TF in response to hypoxia, and hundreds of genes have been reported as HIF targets in different cell types. HIF-1 overexpression enhances the expression of Slug, LDHA, GLUT, TWIST, c-Myc, and VEGF in tumorigenesis, which has been well documented. [42] [43] [44] [45] Hypoxia also induces ATM activation in the absence of DNA damage, but severe hypoxia activates ATM signaling by inducing DNA damage. 51 A recent study showed that ATM can phosphorylate S696 on the inhibitory domain of HIF-1α, which enhances HIF-1α activity under hypoxic conditions. 52 Furthermore, this mediation is mTORC1-dependent, in which phosphorylation and activation of HIF-1α by ATM require mTORC1 suppression. 53 In addition, Guerra et al reported that Myc is required for the activation of the ATM-dependent checkpoints in response to DNA damage. 43 The interplay between oncogenic c-Myc and HIF-1α enhances the metabolic needs of the tumor, which in turn contribute to cancer cell adaptation and survival under hypoxic stress. 54, 55 In the current study, we found that hypoxia might induce KPNA2 expression by regulating the mTOR and ATM pathways, which is consistent with our previous finding that KPNA2 is involved in cell cycle progression, DNA metabolism, DNA repair, transport of cellular components and cell migration. 6 The genetic background of cancer cells is heterogeneous, and defective tumor suppressors or mutated oncogenes promote lung cancer formation and progression. Constitutive activation of the epidermal growth factor receptor (EGFR) caused by EGFR gene mutations was observed in over 60% of cases of lung ADC in Eastern Asia. 56, 57 Several lines of evidence support the hypothesis that ATM kinase is a tumor suppressor gene. 40, 58, 59 Recently, Petersen et al reported that loss of tumor-specific ATM protein expression is an independent prognostic factor in early resected lung cancer. 59 ATM polymorphisms associated with increased lung cancer risk and ATM gene mutations with a concomitant increase in tumor tendency were also described. 58 However, we observed that hypoxia induced ATM activation, which in turn suppressed IRF1, suggesting that the microenvironment plays a critical role in modulating KPNA2 transcription. Although the detailed regulation between EGFR and ATM signaling requires further investigation, the present study reveals that growth stimulation and hypoxia can modulate oncogenic KPNA2 transcription by simultaneously enhancing the expression of its positive regulator E2F1 and suppressing the expression of its negative regulator IRF1 in lung ADC cells.
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